E+H, working with McDermott Will & Emery, has advised Ligand Pharmaceuticals Incorporated on its acquisition of Apeiron Biologics. Baker McKenzie advised Apeiron's shareholders. Dorda reportedly advised Apeiron.
Ligand Pharmaceuticals is a biopharmaceutical company that invests in the clinical development and commercialization of high-value drugs.
Apeiron is a biopharmaceutical company based in Vienna. It holds the royalty rights to the cancer drug Qarziba that it co-developed.
According to E+H, "upon closing of the transaction, Ligand shall acquire all the outstanding shares of Apeiron for USD 100 million in cash. Ligand will also pay Apeiron shareholders additional consideration based on future commercial and regulatory events, including up to USD 28 million if royalties from Apeiron's co-developed drug Qarziba exceed certain pre-determined thresholds."
The E+H team included Partners Alric Ofenheimner, Jana Eichmeyer, Judith Feldner, Florian Sagmeister, Helmut Liebel, and Andreas Zellhofer, Attorney at Law Helena Neuner, and Associates Adrian Walser, Vincenz Stockert, Georg Ball, Yvonne Handler, Marcel Neuhauser, and Rene Renner.
The Baker McKenzie team included Partners Gerhard Hermann, Claudia Fochtmann-Tischler, Lukas Feiler, and Peter Wand, Counsel Philipp Stanek, Senior Associate Andrea Haiden, Associates Ladislav Bulajcsik, Klara Kastner, Jakob Jaritz, and Siba Auf, Junior Associate Silvia Grohmann, and Legal Intern Constantin Huber.
